Find a Product

Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765, Imbruvica) is an FDA approved drug that targets B-cell malignancies and is approved for treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and waldenstrom macroglobulinemia. Orally-bioavailable compound that is a potent and selective inhibitor of bruton's tyrosine kinase (BTK).

Catalog No. Size Price Quantity
92-1243 5 mg $343.00

For account specific pricing, please contact Customer Service at
Ibrutinib (PCI-32765)
Compound Type
Cells were plated in a 384-well plate and incubated overnight at 37°C/5% CO₂ to allow the cells to attach and grow. Cells were then stimulated with a control compound, using the assay conditions described below. Following treatment, signal was detected using the InCELL Hunter Detection Kit according to the recommended protocol.